Anthropic unveils Claude Science platform, empowering developers with advanced AI coding tools and enhanced AI assistant feat

Editorial illustration for Anthropic launches Claude Science, expanding flagship tools for coders

Anthropic launches Claude Science, expanding flagship...

Anthropic launches Claude Science, expanding flagship tools for coders

By AI Daily Post Edited by Brian Petersen, Editor-in-Chief

July 1, 2026 • 2 min read

Anthropic rolled out Claude Science on Tuesday at a gathering of pharmaceutical executives, biotech founders and researchers. The new offering sits beside Claude Code, which targets software engineers, and Claude Cowork, the company’s general‑purpose assistant. While Claude Code executes high‑level coding prompts, Claude Science is built to handle computational biology and drug‑development tasks, drawing on tools that let it run scientific software and query specialized databases.

The product is already accessible to anyone with a paid Claude subscription, and Anthropic says it will also use the system for its own investigations into drugs for rare, neglected diseases. This isn’t the firm’s first step into the lab. In October, it released “Claude for Life Sciences” plug‑ins that let the model tap existing scientific resources, but those were add‑ons rather than a standalone platform.

By promoting Claude Science to the same tier as Claude Code and Claude Cowork, Anthropic signals a deeper commitment to AI‑driven research—though how much of that will translate into tangible breakthroughs remains to be seen.

At an event for pharmaceutical executives, biotech founders, and researchers on Tuesday, Anthropic announced Claude Science, a major new product intended to support scientific research in the same way that Claude Code supports software engineering.

— Anthropic, Claude Science is Anthropic’s newest flagship product - MIT Technology Review - AI Topic Feed

Why this matters

We see Anthropic extending its Claude line with Claude Science, a tool positioned to aid scientific research much as Claude Code assists software engineers. Announced to an audience of pharmaceutical executives, biotech founders, and researchers, the product promises autonomous execution of tasks from concise, high-level prompts and access to specialized tools. Many scientists already rely on Claude Code, and the company notes that coding now permeates much of research, yet not every researcher is a seasoned programmer.

If Claude Science lives up to that premise, it could ease that gap and boost productivity for non‑engineer scientists. However, the announcement offers few details on how the system handles domain‑specific data, validation, or integration with existing lab workflows, leaving it unclear whether the promised autonomy will translate into reliable scientific output. We remain cautious, recognizing the potential for a useful assistant while awaiting concrete evidence of its impact on real‑world research pipelines.